GHK-Cu Dosage: Three Registry Records, None of Them an Injection Trial

Summary: The evidence people cite for injected copper peptide is almost entirely topical, and the registry does not contain what the marketing implies.

This content is for informational purposes only and is not medical advice. Always consult a qualified healthcare provider before starting, changing, or stopping any medication.

GHK-Cu is a copper-binding tripeptide with a real research literature, around 180 records on PubMed. It is sold widely as an injectable research chemical. Those two sentences are both true and the gap between them is the subject of this page.

What the trial registry actually contains

Search ClinicalTrials.gov for the name and three records come back. Open each one and the pattern is immediate.

The first, NCT05932732, is a completed Phase 4 study of 27 participants run by the Austin Institute for Clinical Research. It assesses facial skin quality, hydration and skin barrier across three HydraFacial treatments. GHK-Cu appears as a component of a cosmetic procedure, not as the subject of the trial.

The second, NCT07706361, is listed as not yet recruiting, with 100 participants, sponsored by LifeWave. It studies the effect of that company's X39 patch on circulating GHK and GHK-Cu levels. A patch manufacturer measuring what its own patch does to a biomarker is a legitimate study, and it is not a trial of injected copper peptide either.

The third entry names a sponsor whose registry filings do not survive checking, and it should not be cited as evidence of anything. There is no shortage of genuine material here; that record is not part of it.

So what is the evidence actually about

Overwhelmingly topical and in vitro. The literature that gives GHK-Cu its reputation concerns skin, wound healing and copper transport, studied in cell systems, animals, and cosmetic formulations applied to the skin.

That is a real body of work. It is also a body of work about a molecule delivered to the surface, and the route is not incidental to what a copper complex does.

What that means for a dosage figure

A ghk cu dosage chart for an injectable preparation is therefore in an awkward position. There is no registered injection trial to restate, no approved product anywhere, and no regulator has set a quantity.

What can honestly be said is what the topical work used, in what preparation, and on what tissue. A chart that presents injection quantities without noting that the evidence base is topical has crossed from reporting into inference, and the change is invisible in a table.

The check worth doing

Open all three registry records and read the study type and the intervention field. Two of them are about a facial procedure and a patch. That takes about a minute, and it reframes the compound more usefully than any summary of the literature.